| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases
Decoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safety profiles consistent with each agent
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces recent updates for the ongoing INDP-D101 clinical trial.
Posted In: INDP
